阿莫西林与莫西沙星治疗幽门螺旋杆菌胃病的临床疗效及药理学分析
|
摘要
目的研究在幽门螺旋杆菌胃病治疗中采用莫西沙星与阿莫西林的效果。方法样本方便选自该院2017年3月—2018年3月收治的180例幽门螺旋杆菌胃病患者,按照随机的原则将患者分为对照组与观察组,每组患者90例,对照组患者为阿莫西林患者,观察组患者为采用莫西沙星治疗患者,比较两组患者缓解率、不良反应发生率、预后生活质量。结果观察组90例患者总缓解率为93.3%,对照组90例患者总缓解率为64.4%;观察组患者不良反应发生率为3.3%;对照组患者发生率为21.1%,不良反应发生情况差异显著,其中观察组患者治疗后较为优异(χ~2=6.5312,P<0.05)。结论在幽门螺旋杆菌胃病患者治疗中采用莫西沙星治疗,可有效改善患者不良反应发生情况。
Objective To study the effects of moxifloxacin and amoxicillin in the treatment of Helicobacter pylori. Methods The samples were convenient selected from 180 patients with Helicobacter pylori stomach disease admitted from March2017 to March 2018 in our hospital. The patients were divided into control group and observation group according to the principle of randomness. 90 patients in each, the control group was treated with moxilin, the patients in the observation group were treated with moxifloxacin, and the remission rate, adverse reaction rate, and prognosis quality of life were compared between the two groups. Results The total remission rate was 93.3% in 90 patients in the observation group, 64.4% in90 patients in the control group, 3.3% in the observation group, and 21.1% in the control group. Significantly, the patients in the observation group were superior after treatment(χ~2=6.531 2,P<0.05). Conclusion Moxifloxacin treatment in patients with Helicobacter pylori stomach disease can effectively improve the occurrence of adverse reactions in patients.
Objective To study the effects of moxifloxacin and amoxicillin in the treatment of Helicobacter pylori. Methods The samples were convenient selected from 180 patients with Helicobacter pylori stomach disease admitted from March2017 to March 2018 in our hospital. The patients were divided into control group and observation group according to the principle of randomness. 90 patients in each, the control group was treated with moxilin, the patients in the observation group were treated with moxifloxacin, and the remission rate, adverse reaction rate, and prognosis quality of life were compared between the two groups. Results The total remission rate was 93.3% in 90 patients in the observation group, 64.4% in90 patients in the control group, 3.3% in the observation group, and 21.1% in the control group. Significantly, the patients in the observation group were superior after treatment(χ~2=6.531 2,P<0.05). Conclusion Moxifloxacin treatment in patients with Helicobacter pylori stomach disease can effectively improve the occurrence of adverse reactions in patients.
引文
[1]于萍,王景慧,王秀英,等.阿莫西林与莫西沙星治疗幽门螺旋杆菌胃病的临床疗效及药理学分析[J].中国继续医学教育,2017,19(9):200-201.
[2]张雪娇,陈征远,刘志东.探讨莫西沙星与阿莫西林治疗幽门螺旋杆菌胃病的治疗效果[J].中国保健营养,2014(5下旬刊):2866.
[3]谢秋云.阿莫西林与莫西沙星治疗幽门螺旋杆菌胃病的临床疗效及药理学分析[J].北方药学,2016,13(4):173-174.
[4]赵艳霞.探讨不同药物对幽门螺旋杆菌引起的胃病的治疗效果[J].健康必读,2012(4中旬刊):246.
[5]张洪义.不同药物对幽门螺旋杆菌引起的胃病的疗效分析[J].中国现代医生,2010(21):144-145.
[6]易加培.探讨不同药物对幽门螺旋杆菌引起的胃病的治疗效果[J].中国保健营养,2014(6上旬刊):3429-3430.
[7]汪洋.不同药物对幽门螺旋杆菌引起胃病的疗效分析[J].医学信息,2010(7下旬刊):311.
[8]张海星.抗幽门螺旋杆菌药物联合应用治疗门脉高压性胃病的临床效果[J].中外健康文摘,2012(47):167-168.
[9]苗建香,韩静.痢特灵联合维生素B6和康复新液对幽门螺旋杆菌的抑制效果[J].健康前沿,2017(9):180.
[10] Saad RJ,Chey WD.Persistent Helicobacter pylori infection after a course of antimicrobial therapy-what's next[J].Clinical gastroenterology and hepatology:the official clinical practice journal of the American Gastroenterol ogical Association,2018(10):1086-1090.
[11] Adjéka Stanislas Doffou,Koffi Alain Attia,Mamert Fulgence Yao Bathaix, et al.The Helicobacter pylori Eradication Rate in a High Prevalence Area(West Africa):Three Triple Therapy Comparative Study[J].Open Journal of Gastroenterology,2015(12):200-206.
[12]邹维青.HP感染的慢性胃病含铋剂10天四联疗法的HP根除效果观察[J].中国社区医师:医学专业,2012,4(19):72.
[2]张雪娇,陈征远,刘志东.探讨莫西沙星与阿莫西林治疗幽门螺旋杆菌胃病的治疗效果[J].中国保健营养,2014(5下旬刊):2866.
[3]谢秋云.阿莫西林与莫西沙星治疗幽门螺旋杆菌胃病的临床疗效及药理学分析[J].北方药学,2016,13(4):173-174.
[4]赵艳霞.探讨不同药物对幽门螺旋杆菌引起的胃病的治疗效果[J].健康必读,2012(4中旬刊):246.
[5]张洪义.不同药物对幽门螺旋杆菌引起的胃病的疗效分析[J].中国现代医生,2010(21):144-145.
[6]易加培.探讨不同药物对幽门螺旋杆菌引起的胃病的治疗效果[J].中国保健营养,2014(6上旬刊):3429-3430.
[7]汪洋.不同药物对幽门螺旋杆菌引起胃病的疗效分析[J].医学信息,2010(7下旬刊):311.
[8]张海星.抗幽门螺旋杆菌药物联合应用治疗门脉高压性胃病的临床效果[J].中外健康文摘,2012(47):167-168.
[9]苗建香,韩静.痢特灵联合维生素B6和康复新液对幽门螺旋杆菌的抑制效果[J].健康前沿,2017(9):180.
[10] Saad RJ,Chey WD.Persistent Helicobacter pylori infection after a course of antimicrobial therapy-what's next[J].Clinical gastroenterology and hepatology:the official clinical practice journal of the American Gastroenterol ogical Association,2018(10):1086-1090.
[11] Adjéka Stanislas Doffou,Koffi Alain Attia,Mamert Fulgence Yao Bathaix, et al.The Helicobacter pylori Eradication Rate in a High Prevalence Area(West Africa):Three Triple Therapy Comparative Study[J].Open Journal of Gastroenterology,2015(12):200-206.
[12]邹维青.HP感染的慢性胃病含铋剂10天四联疗法的HP根除效果观察[J].中国社区医师:医学专业,2012,4(19):72.